Medicine
Lithostat 250 mg tablet
Lithostat 250 mg tablet is a prescription medicine containing Acetohydroxamic acid for oral use, marketed by Mission Pharmacal, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
LITHOSTAT ® should be stored in a dry place at room temperature, 15° - 30°C…
Key facts
- Active ingredient (INN)
- Acetohydroxamic acid
- Brand
- Lithostat
- Strength
- 250 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets
- Marketing authorisation holder
- Mission Pharmacal
- Manufacturer
- Mission Pharmacal
- Origin register
- US FDA, United States
- Storage
- LITHOSTAT ® should be stored in a dry place at room temperature, 15° - 30°C (59° - 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- G04BX03 Acetohydroxamic acid
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 31 May 1983
- Identifiers
- RxCUI 197308, 213557DailyMed set ID 6660b616-a82d-9109-19ce-2bdf9747aceaNDC 0178-0500Application NDA018749
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet in 1 bottle | 0178-0500-01 | Mission Pharmacal | 31 May 1983 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 31 May 1983 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Acetohydroxamic acid is a urease inhibitor indicated as adjunctive therapy in patients with chronic urea-splitting urinary infection. It is available as tablets for oral use. MedsAcross supplies Acetohydroxamic acid for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Acetohydroxamic acidFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Lithostat prescribing information (Mission Pharmacal) · U.S. National Library of Medicine, DailyMed
Need Lithostat 250 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.